Combining two drugs before surgery for mouth cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests two newer drugs (one targeted therapy, one immunotherapy) given before surgery to shrink mouth cancer and improve outcomes. The goal is to see if combining them is safe and effective for people with stage III-IVA disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have newly diagnosed mouth cancer (specifically squamous cell carcinoma) that hasn't been treated yet.
- Your cancer is at a stage where surgery could potentially remove it (stage III or IVA).
- You are generally able to do daily activities and light chores without help (ECOG score 0 or 1).
- Your cancer tests positive for a protein called PD-L1, which the treatment targets.
- You don't have serious heart, liver, kidney, or blood problems, and you're not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This trial tests a combination of two drugs (benmelstobart and anlotinib) given with standard chemotherapy before surgery in people with advanced mouth cancer. The goal is to see if this combination can shrink the tumor and improve the chance of successful treatment.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
This trial tests whether combining two immunotherapy drugs before surgery is better than one alone for advanced head and neck cancer. The goal is to see if the combination can shrink tumors more and improve outcomes.
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
Hear when a new Oral Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.